US6825169B1
(en)
|
1991-10-22 |
2004-11-30 |
Trustees Of Tufts College |
Inhibitors of dipeptidyl-aminopeptidase type IV
|
IL111785A0
(en)
*
|
1993-12-03 |
1995-01-24 |
Ferring Bv |
Dp-iv inhibitors and pharmaceutical compositions containing them
|
WO1995034538A2
(en)
*
|
1994-06-10 |
1995-12-21 |
Universitaire Instelling Antwerpen |
Purification of serine proteases and synthetic inhibitors thereof
|
FR2733995B1
(fr)
*
|
1995-05-09 |
1997-07-25 |
Inst Nat Sante Rech Med |
Inhibiteurs de l'inactivation de neuropeptides endogenes notamment la cholecystokinine, leurs procedes de preparation leur utilisation comme medicaments et procede de criblage de medicaments
|
DE122010000020I1
(de)
|
1996-04-25 |
2010-07-08 |
Prosidion Ltd |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
US5965532A
(en)
*
|
1996-06-28 |
1999-10-12 |
Trustees Of Tufts College |
Multivalent compounds for crosslinking receptors and uses thereof
|
US6011155A
(en)
*
|
1996-11-07 |
2000-01-04 |
Novartis Ag |
N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
US6100234A
(en)
*
|
1997-05-07 |
2000-08-08 |
Tufts University |
Treatment of HIV
|
US6040145A
(en)
|
1997-05-07 |
2000-03-21 |
Tufts University |
Potentiation of the immune response
|
CA2304206A1
(en)
|
1997-09-29 |
1999-04-08 |
Point Therapeutics, Inc. |
Stimulation of hematopoietic cells in vitro
|
DE04029691T1
(de)
|
1998-02-02 |
2007-11-08 |
Trustees Of Tufts College, Medford |
Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus
|
KR20010052302A
(ko)
|
1998-05-04 |
2001-06-25 |
바바라 피. 월너 |
조혈 자극
|
DE19823831A1
(de)
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
EP1084129B1
(de)
|
1998-06-05 |
2003-01-22 |
Point Therapeutics, Inc. |
Cyclische boroprolinverbindungen
|
DE19828114A1
(de)
*
|
1998-06-24 |
2000-01-27 |
Probiodrug Ges Fuer Arzneim |
Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
|
DE19828113A1
(de)
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
DE19834591A1
(de)
|
1998-07-31 |
2000-02-03 |
Probiodrug Ges Fuer Arzneim |
Verfahren zur Steigerung des Blutglukosespiegels in Säugern
|
JP2002523365A
(ja)
*
|
1998-08-21 |
2002-07-30 |
ポイント セラピューティクス, インコーポレイテッド |
基質の活性の調節
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
CO5150173A1
(es)
*
|
1998-12-10 |
2002-04-29 |
Novartis Ag |
Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
|
GB9906715D0
(en)
*
|
1999-03-23 |
1999-05-19 |
Ferring Bv |
Compositions for promoting growth
|
GB9906714D0
(en)
*
|
1999-03-23 |
1999-05-19 |
Ferring Bv |
Compositions for improving fertility
|
US6890904B1
(en)
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
DE19926233C1
(de)
|
1999-06-10 |
2000-10-19 |
Probiodrug Ges Fuer Arzneim |
Verfahren zur Herstellung von Thiazolidin
|
US6110949A
(en)
*
|
1999-06-24 |
2000-08-29 |
Novartis Ag |
N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
US6172081B1
(en)
|
1999-06-24 |
2001-01-09 |
Novartis Ag |
Tetrahydroisoquinoline 3-carboxamide derivatives
|
US6617340B1
(en)
|
1999-07-29 |
2003-09-09 |
Novartis Ag |
N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
DE19940130A1
(de)
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
AU1916401A
(en)
*
|
1999-11-12 |
2001-06-06 |
Guilford Pharmaceuticals Inc. |
Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
KR20080067009A
(ko)
|
2000-03-31 |
2008-07-17 |
프로시디온 리미티드 |
디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
|
US7132104B1
(en)
|
2000-10-27 |
2006-11-07 |
Probiodrug Ag |
Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
|
US6890905B2
(en)
|
2001-04-02 |
2005-05-10 |
Prosidion Limited |
Methods for improving islet signaling in diabetes mellitus and for its prevention
|
US20030130199A1
(en)
|
2001-06-27 |
2003-07-10 |
Von Hoersten Stephan |
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
|
US7368421B2
(en)
|
2001-06-27 |
2008-05-06 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
|
DE10150203A1
(de)
|
2001-10-12 |
2003-04-17 |
Probiodrug Ag |
Peptidylketone als Inhibitoren der DPIV
|
WO2003002531A2
(en)
|
2001-06-27 |
2003-01-09 |
Smithkline Beecham Corporation |
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
|
US6844316B2
(en)
|
2001-09-06 |
2005-01-18 |
Probiodrug Ag |
Inhibitors of dipeptidyl peptidase I
|
CA2466870A1
(en)
|
2001-11-26 |
2003-06-05 |
Trustees Of Tufts College |
Methods for treating autoimmune disorders, and reagents related thereto
|
WO2003045977A2
(en)
*
|
2001-11-26 |
2003-06-05 |
Trustees Of Tufts College |
Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
|
JP2005527504A
(ja)
|
2002-02-28 |
2005-09-15 |
プロシディオン・リミテッド |
グルタミニルを基礎するdpiv阻害剤
|
WO2003092605A2
(en)
*
|
2002-04-30 |
2003-11-13 |
Trustees Of Tufts College |
Protease inhibitors
|
US7687625B2
(en)
|
2003-03-25 |
2010-03-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7371871B2
(en)
|
2003-05-05 |
2008-05-13 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
KR20100106630A
(ko)
|
2003-05-05 |
2010-10-01 |
프로비오드룩 아게 |
글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CN1867560A
(zh)
|
2003-08-13 |
2006-11-22 |
武田药品工株式会社 |
4-嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途
|
JP5707014B2
(ja)
|
2003-10-15 |
2015-04-22 |
プロビオドルグ エージー |
グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用
|
US7767828B2
(en)
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
WO2005047297A1
(en)
|
2003-11-12 |
2005-05-26 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
BRPI0418639B8
(pt)
|
2004-03-15 |
2021-05-25 |
Takeda Pharmaceutical |
compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos
|
WO2005118555A1
(en)
|
2004-06-04 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
EP1794120B1
(de)
|
2004-07-23 |
2012-04-11 |
Nuada, LLC |
Peptidaseinhibitoren
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
US7399869B2
(en)
|
2005-05-19 |
2008-07-15 |
Genentech, Inc. |
Fibroblast activation protein inhibitor compounds and methods
|
US7825139B2
(en)
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
NZ566799A
(en)
|
2005-09-14 |
2011-04-29 |
Takeda Pharmaceutical |
Dipeptidyl peptidase inhibitors for treating diabetes
|
CN101360723A
(zh)
|
2005-09-16 |
2009-02-04 |
武田药品工业株式会社 |
制备嘧啶二酮衍生物的方法
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
WO2007120689A2
(en)
|
2006-04-11 |
2007-10-25 |
Arena Pharmaceuticals, Inc. |
Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
|
CA2651089C
(en)
|
2006-05-04 |
2018-02-20 |
Peter Sieger |
A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
EP2146210A1
(de)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
MX2012011631A
(es)
|
2010-04-06 |
2013-01-18 |
Arena Pharm Inc |
Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
|
US10894787B2
(en)
|
2010-09-22 |
2021-01-19 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
WO2012135570A1
(en)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145604A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
CN107683135A
(zh)
|
2015-03-09 |
2018-02-09 |
因特克林医疗有限公司 |
用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
|
AU2018249822A1
(en)
|
2017-04-03 |
2019-10-31 |
Coherus Biosciences Inc. |
PPArgamma agonist for treatment of progressive supranuclear palsy
|